NCT07111416

Brief Summary

The goal of this observational study is to learn why some adults over the age of 65, have A1c tests that do not match up with their blood glucose levels, also known as 'A1c-glucose discordance'. The main question it aims to answer is: Could alternative tests like CGM or personalized A1c provide more accurate diabetes screening in this population? Participants will be asked to perform blood tests every week to two weeks and wear a CGM for up to 8 weeks.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
45

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2025

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 1, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 8, 2025

Completed
24 days until next milestone

Study Start

First participant enrolled

September 1, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

August 8, 2025

Status Verified

August 1, 2025

Enrollment Period

7 months

First QC Date

August 1, 2025

Last Update Submit

August 1, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Calculate the Mean Absolute Difference Between A1c-Derived Estimated Average Glucose (eAG) and CGM-Derived eAG

    Determine the mean absolute difference between estimated average glucose (eAG) calculated from hemoglobin A1c and eAG derived from Continuous Glucose Monitoring (CGM) data. This measure will be assessed among participants suspected of having discordance between A1c values and actual blood glucose levels.

    From 1 week after enrollment to the end of their enrollment at either week 5 or week 10

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Individuals 65 years of age and older, who have evidence of A1c-glucose discordance without either a diagnosis of type 2 diabetes or current/ prior treatment for type 2 diabetes

You may qualify if:

  • Age 65 years of age or older
  • A1c 5.3% - 7.4% without a diagnosis on the problem list and/or current or prior treatment for diabetes
  • Evidence of A1c discordance by meeting one of two criteria developed by an EHR based algorithm
  • At least five (5) HbA1c values and three (3) CBC values available in the EHR in the previous 10 years
  • Willingness to wear an Abbott Freestyle Libre 3 System Sensor for up to 48 days
  • Willingness to consent to data collection using the electronic health record and sign a medical release to obtain future medical records from other health care facilities

You may not qualify if:

  • Known or suspected diabetes of other causes (type 1 diabetes, pancreatogenic diabetes, monogenic diabetes, etc.)
  • Clinically significant anemia based on most recent hematocrit (M = \<38%, F \<33%) and/or hemoglobin (M = \<12 g/dL, F = \<10 g/dL) within the last 12 months
  • Condition with short life expectancy
  • Blood (hematologic) malignancy
  • rtCGM-interference agents per manufacturer (e.g., high dose vitamin C)
  • Unstable psychiatric or medical condition
  • Active treatment for cancer, planned treatment for cancer, or recent active cancer with a likelihood of recurrence or progression, that, in the opinion of the site investigator, would interfere with study therapy prior to 2029
  • Allowed Exceptions: Treated cancer with no evidence of disease, no evidence of disease progression, and no planned change in therapy. Examples of allowable cancers include:
  • Breast cancer stable after active treatment, managed with long-term anti-estrogen therapy
  • Prostate cancer being observed
  • Stage 0 or 1 tumors status post resection or other definitive treatment
  • Other similarly stable cancer comorbidities

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

August 1, 2025

First Posted

August 8, 2025

Study Start

September 1, 2025

Primary Completion

April 1, 2026

Study Completion

May 1, 2026

Last Updated

August 8, 2025

Record last verified: 2025-08